Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Megiorni F, Camero S, Ceccarelli S, McDowell HP, Mannarino O, Marampon F, Pizer B, Shukla R, Pizzuti A, Marchese C, Clerico A, Dominici C. Megiorni F, et al. Among authors: marchese c. Oncotarget. 2016 Nov 29;7(48):79342-79356. doi: 10.18632/oncotarget.12688. Oncotarget. 2016. PMID: 27764816 Free PMC article.
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
Megiorni F, Gravina GL, Camero S, Ceccarelli S, Del Fattore A, Desiderio V, Papaccio F, McDowell HP, Shukla R, Pizzuti A, Beirinckx F, Pujuguet P, Saniere L, der Aar EV, Maggio R, De Felice F, Marchese C, Dominici C, Tombolini V, Festuccia C, Marampon F. Megiorni F, et al. Among authors: marchese c. J Hematol Oncol. 2017 Oct 6;10(1):161. doi: 10.1186/s13045-017-0530-z. J Hematol Oncol. 2017. PMID: 28985758 Free PMC article.
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Camero S, Ceccarelli S, De Felice F, Marampon F, Mannarino O, Camicia L, Vescarelli E, Pontecorvi P, Pizer B, Shukla R, Schiavetti A, Mollace MG, Pizzuti A, Tombolini V, Marchese C, Megiorni F, Dominici C. Camero S, et al. Among authors: marchese c. J Cancer Res Clin Oncol. 2019 Jan;145(1):137-152. doi: 10.1007/s00432-018-2774-6. Epub 2018 Oct 24. J Cancer Res Clin Oncol. 2019. PMID: 30357520 Free PMC article.
Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells.
Ceccarelli S, Megiorni F, Bellavia D, Marchese C, Screpanti I, Checquolo S. Ceccarelli S, et al. Among authors: marchese c. Stem Cells Int. 2019 Jan 6;2019:6264931. doi: 10.1155/2019/6264931. eCollection 2019. Stem Cells Int. 2019. PMID: 30723507 Free PMC article. Review.
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, De Vitis C, Camero S, Marchetti C, Mancini R, Benedetti Panici P, Dominici C, Romano F, Angeloni A, Marchese C, Ceccarelli S. Vescarelli E, et al. Among authors: marchese c. J Exp Clin Cancer Res. 2020 Jan 2;39(1):3. doi: 10.1186/s13046-019-1490-7. J Exp Clin Cancer Res. 2020. PMID: 31898520 Free PMC article.
171 results